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The number of patients suffering from diabetes mellitus (DM)
dramatically increasing. In 2011 the international diabetes federa
tion project (IDF) indicated that the number of diabetic patient
was more than 360 million worldwide.1 In 2001 this number wa
predicted to be reached in 2030 only.2 More than 90% of the diag
nosed cases belong to type 2 or non-insulin dependent diabete
mellitus (T2DM or NIDDM) characterized by peripheral insuli
resistance, elevated hepatic glucose production, and defects i
pancreatic insulin secretion.3 Although several drugs are in clinica
use for symptomatic treatment of T2DM,4,5 these therapies ar
inadequate for 30–40% of the patients.6
Among several investigational ﬁelds to diminish hepat
glucose output in T2DM, glycogen phosphorylase (GP) as a mai
regulatory enzyme of glycogen metabolism has become a validate
target.2
1
Contents lists availab
Bioorganic & Medi
journal homepage: wwProtein crystallographic studies have shown that endogenous
and synthetic modulators can bind to six major sites in GP: the
catalytic, the inhibitor, the allosteric (or AMP-binding), the glyco-
gen storage, and the new allosteric sites,7 as well as the newly
discovered benzimidazole site.8 A number of GP inhibitors for the
different binding sites have been disclosed and several of them
have considerable in vivo effects towards normalizing blood
glucose and liver glycogen levels.9,10
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In recent years, the interaction of GP and glycogen targetin
subunit (GL) of protein phosphatase 1 (PP1) has been identiﬁe
as a novel molecular target for the treatment of T2DM.11–13
was demonstrated in an in vivo mouse model that disruption o
GL–GP interaction resulted in an increased glycogen synthas
activity and the mice had improved glucose tolerance.14 X-ra
crystallography showed that the GL–GP interaction took place b
binding the C-terminal region of GL to the allosteric site of GP.1
Thus, occupation of this site may prevent GL–GP interaction, there
by enhancing glycogen synthesis which, on the other hand, dimin
ishes hepatic glucose production. This effect could be achieved b
modulators that bind to the allosteric site of GP.
Several molecules of high structural diversity were reported t
bind to the allosteric site of GP, such as derivatives of acyl ure
dihydropyridine dicarboxylic acid, pentanedioic acid, phthalic acid
N,N0-diaryl-urea, and pentacyclic triterpenoids.9,16
HOOC
COOH
O
O
O
OH
HO
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FR258900
1
core unit
IC50 = 2.5 μM (human liver GP)17
Ki = 0.46 μM (rabbit muscle GP)18. Lett. (2013), http://dx.doi.org/10.1016/j.bmcl.2013.01.042
FR258900, a bis-O-(p-coumaroylated)2,3-dihydroxypentane-
dioic acid derivative 1, was isolated from the fermentation broth
of fungi No. 138354.17 The compound was shown to inhibit glyco-
80 gen phosphorylases and to bind to the allosteric site of GP.18 Com-
pound 1 stimulated glycogen synthesis in primary rat hepatocytes,
and investigations on glucagon-induced hyperglycemia in C57BL/6
mice suggested that 1 could suppress hepatic glucose output in
vivo.19
On the basis of the above information and as a continuation of
our research on the design and synthesis of small molecule inhib-
itors of GP we envisaged the preparation of structural analogues of
1. Since the synthesis of 2,3-dihydroxy-pentanedioic acid is un-
known in the literature, the core unit was planned to be replaced
90 by easily available tartaric acid, also allowing to study the inﬂu-
ence of conﬁgurational isomerism on the biological activity. Fur-
thermore, the substitution pattern of the aromatic rings was also
modiﬁed.
A similar derivative to our target compounds is chicoric acid20
(2) with immunostimulator and HIV-1 integrase inhibitor activi-
ties.21
O
O
COOH
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Crucial points for both the syntheses of chicoric acid20–23 and
100 the preparation of our target compounds are the protections of
phenolic OH and COOH groups. Acylation of unprotected tartaric
acids with carbonylcaffeoyl chloride is feasible, but this carbonate
type protection can be used only for caffeic acid.20 Benzylic protec-
tion of both functionalities seemed very attractive, however, for
the removal an equimolar amount of Pd(OAc)2 for each protective
group was necessary rendering this method extremely expen-
sive.23 Orthogonal ester type protection (acetyl for OH and tert-bu-
tyl for COOH22 or methoxycarbonyl for OH and diphenylmethyl for
COOH21) were also applied in the syntheses of 2 and their ana-
110 logues. Our comparative preliminary experiments showed that
introduction of the latter pair of protecting groups was more efﬁ-
cient and easier to reproduce than that of the benzylic protection.
Thus, the COOH groups of D-, L- and meso-tartaric acids (3–5)
were transformed into diphenylmethyl (DPM) esters (7–9) by
diphenyldiazomethane (DPDAM) generated in situ from benzophe-
none-hydrazone (6) by oxidation with activated MnO2 in CH2Cl224
(Scheme 1). DPM esters 7–9 were isolated in excellent yields as
white crystals and used further without any puriﬁcation.
Next, acid-chlorides 15–17 were prepared from commercially
120 available cinnamic (10), p-coumaric (11), and ferulic acids (12),
respectively (Scheme 2), whereby phenolic OH groups of 11 and
12 were protected as methyl-carbonates 13 and 14, respectively.
Thionyl-chloride treatment of carboxylic acids 10, 13, and 14 gave
acid-chlorides 15–17 which were used for acylations without fur-
ther puriﬁcation.
Acylations of 7–9 were carried out in dry toluene using
2.2 equiv of acid-chlorides 15–17 and 2.2 equiv dry pyridine as
base (Scheme 3). The fully protected 18–25 were isolated by col-
umn chromatography in acceptable yields.
130Subsequent deprotections following the suggested protocol21
(removal of methoxycarbonyl groups with Na2CO3/aq THF and
cleavage of DPM esters with 70% aq AcOH) caused in our hands to-
tal decomposition of the molecules, irrespective of the order of the
deprotection steps.
Therefore, a new protocol for the cleavage of protecting groups
in 18–25was developed. The DPM esters could be cleaved by using
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a then b
10 - 14 15 - 17
or b
R1
R2
COOH R1
R2
COOR3
a: ClCOOCH3 in 50% aq. NaOH at 0 °C; b: SOCl2, reflux, 6 h.
R1 R2 R3 Yield (%) Abbreviation
10 H H Cinn-OH
11 H OH Coum-OH
12 OCH3 OH Feru-OH
13 H OCOOCH3 OH 84 4-MC-Coum-OH
14 OCH3 OCOOCH3 OH 88 4-MC-Feru-OH
15 H H Cl 100* 4-MC-Cinn-Cl
16 H OCOOCH3 Cl 100* 4-MC-Coum-Cl
17 OCH3 OCOOCH3 Cl 100* 4-MC-Feru-Cl
* Conversion of the starting material.
Scheme 2. Preparation of acid chlorides 15–17.
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PlPh2CN2
dry CH2Cl2
rt.
3 - 5 7 - 9
DPMOOC
OH
COODPM
HO
COOH
HO
HOOC
OH
Starting compound Configuration Product Yield (%) 
3 D or (2S,3S) 7 85 
4 L or (2R,3R) 8 83 
5 meso or (2R,3S) 9 82 onScheme 1. Preparation of DPM esters 7–9.
ease cite this article in press as: Varga, G.; et al. Bioorg. Med. Chem. Letty anisole–TFA reagent in dry CH2Cl2 at room temperature.25 Puri-
ation of the crude products by column chromatography
hCH3:AcOH 3:1) gave 26–33 in good to excellent yields (Scheme
. Hydrolysis of the methoxycarbonyl esters was achieved by
ing an aq solution of NH3 in MeOH and the products 34–39were
lated in good to excellent yields. Reversing of the sequence re-
lted in decomposition of the molecules in the ﬁrst step. The
ucture of the molecules was identiﬁed by NMR and MS
easurements.
The synthesized derivatives were evaluated as inhibitors of rab-
muscle glycogen phosphorylase b (rmGPb), and the results are
mmarized in Table 1. For comparison FR258900 (1) was also
sted under our conditions. Compound 1 proved a competitive
hibitor against AMP and the obtained Ki of 0.2 lM showed a good
reement with the literature value. When tested against G1P, 1
peared as a non-competitive inhibitor with a Ki of 5.47 lM
lease, see Fig. 1 in the Supplementary data for details of the mea-
rements and plots of the data). Similar conclusions could be
awn from the kinetic studies of compounds 32–39, as well,
ereby indicating that in general the tartaric acid derivatives
und to the same site as FR258900 (1).
As non-competitive inhibitors against G1P, the cinnamoyl
rivatives 32 and 33, lacking the 4-OH substituents characteristic
the natural product 1, proved practically inefﬁcient. In the
coumaroyl (34–36) and feruloyl (37–39) series the meso-conﬁg-
ed compounds 36 and 39 proved most efﬁcient. The latter dem-
strated that introduction of an additional substituent in the
. (2013), http://dx.doi.org/10.1016/j.bmcl.2013.01.042
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Scheme 3. Acylatioaromatic rings (3-CH3O) was very advantageous and 39 proved
equipotent with 1.
As competitive inhibitors against AMP, beside the meso-conﬁg-
ured 36 and 39, the L-conﬁgured 38 proved most efﬁcient. Never-
theless, the efﬁciency of the inhibitors lagged behind that of 1.
The presence of the 3-CH3O moieties in 39 rendered this com-
pound the best inhibitor under these test conditions, as well.
In order to determine the molecular basis of the efﬁciency of
these synthetic compounds, preparation of further analogues as
26 - 31
Products A
R Starting compound(Configuration) Products A
Cinn 18 (D) -19 (L) -
20 (D) 26
4-MC-Coum 21 (L) 27
22 (meso) 28
23 (D) 29
4-MC-Feru 24 (L) 30
25 (meso) 31
Scheme 4. Cleavage o
Table 1
Inhibition (Ki [lM]) of rabbit muscle glycogen phosphorylase b by the synthetic
compounds
Compound (conﬁguration) G1P dependence AMP dependence
1 (La) 5.47 0.20
0.4618
32 (D) 800b —
33 (L) No inh. —
34 (D) 109 26.4
35 (L) 300b —
36 (meso) 71.4 5.68
37 (D) 29.1 19.0
38 (L) 28.5 2.68
39 (meso) 3.36 2.0
a Conﬁguration of the natural product corresponds to that of L-tartaric acid.
b Calculated from the IC50 value by using a web-based tool.26
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Products B
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idine
ne, r.t.
18 - 25
DPMOOC
O
COODPM
O R
R
Product (Configuration) Yield (%)
18 (D)
19 (L)
63
52
20 (D)
21 (L)
22 (meso)
54
48
83
23 (D)
24 (L)
25 (meso)
48
50
43
ith acid chlorides 15–17.well as molecular dockings and X-ray crystallographic studies are
in progress, and will be reported in due course.
In conclusion, three series of D-, L- and meso-tartaric acids di-O-
acylated by cinnamic, p-coumaric, and ferulic acids were prepared
as synthetic analogues of FR258900, a natural product with
glycogen phosphorylase inhibitory and in vivo antihyperglycemic
activities. The syntheses were characterized by using methoxycar-
180bonyl (MC) and diphenylmethyl (DPM) esters to protect phenolic
OH and COOH groups, respectively. New methods were applied
for the removal of these protective groups (anisole–TFA for the
cleavage of DPM, aq NH3–MeOH to hydrolyse MC). Some of the
new compounds proved inhibitors of rabbit muscle glycogen phos-
phorylase b (competitive inhibition against AMP, non-competitive
against G1P) in the low micromolar range. It was demonstrated by
this work that simple synthetic compounds can bind to rmGPb
similarly to the natural product, thereby opening up a new way
for further studies of allosteric site inhibitors. The synthetic avail-
190ability of these analogs offers obvious advantages over FR258900.
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